Comparative Pharmacology
Head-to-head clinical analysis: DAYPRO versus RUFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DAYPRO versus RUFEN.
DAYPRO vs RUFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and thereby alleviating pain and inflammation.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, decreasing prostaglandin synthesis.
600 mg orally once daily; max 1200 mg/day
400-800 mg orally three to four times daily; maximum 3200 mg/day.
None Documented
None Documented
Approximately 40-70 hours (mean ~50 h), allowing once-daily dosing; steady-state reached in 4-6 days.
Terminal elimination half-life is 2-4 hours; clinical context: short half-life requires frequent dosing for sustained analgesia.
Renal (approx. 70-80% as unchanged drug and glucuronide conjugate; biliary/fecal excretion accounts for the remainder).
Primarily renal (approximately 90% as glucuronide conjugates and unchanged drug), with minor biliary/fecal elimination (<10%).
Category C
Category C
Nonsteroidal Anti-Inflammatory Drug (NSAID)
Nonsteroidal Anti-Inflammatory Drug (NSAID)